3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
6
Phase 1
5
Phase NA
1
Phase 3
1
Phase 1/2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Leukemia, Lymphocytic, Chronic, B-Cell
24
Lymphoma, Non-Hodgkin
17
Lymphoma, Follicular
14
Lymphoma, Mantle-Cell
9
Lymphoma
6
Lymphoma, B-Cell, Marginal Zone
5
Recurrence
3
Neoplasms
3
Lymphoma, Large B-Cell, Diffuse
3
Lymphoma, B-Cell
2
Leukemia
2
Hematologic Diseases
2
Waldenstrom Macroglobulinemia
1
Tumor Lysis Syndrome
1
Multiple Myeloma
1
Lymphoma, T-Cell, Peripheral
1
Leukemia, B-Cell
1
Immunoblastic Lymphadenopathy
1
Hodgkin Disease
1
Chromosome 17 deletion
1
Interventions
ibrutinib
4
Rituximab
4
fludarabine phosphate
3
Peripheral Blood Stem Cell Transplantation
3
liposomal amphotericin B
2
idelalisib
2
Whole-Body Irradiation
2
Mycophenolic Acid
2
Epoetin Alfa
2
Early Intervention, Educational
2
Darbepoetin alfa
2
Cyclosporins
2
Cyclosporine
2
Chlorambucil
2
zanubrutinib
1
fludarabine
1
ferrous sulfate
1
ferric gluconate
1
Vancomycin
1
Tazobactam
1
Sucrose
1
Sirolimus
1
Psychiatric Rehabilitation
1
Piperacillin, Tazobactam Drug Combination
1
Piperacillin
1
Pharmacogenomic Testing
1
Ondansetron
1
Morphine
1
Ketamine
1
Interferon-alpha
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Waldenstrom Macroglobulinemia
×
Bendamustine Hydrochloride
×
Clear all
NCT01732926
2018-11-16
Bridalveil
Gilead Sciences
Phase 3
Terminated
475 enrolled
9 charts